Treatment of Inflammatory Bowel Disease with Biologics , Softcover reprint of the original 1st ed. 2018

Coordinators: Cheifetz Adam S., Feuerstein Joseph D.

Language: English

105.49 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
Treatment of Inflammatory Bowel Disease with Biologics
Publication date:
Support: Print on demand

147.69 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
Treatment of Inflammatory Bowel Disease with Biologics
Publication date:
Support: Print on demand

This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn?s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field.

Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.

1. Mechanism of Action and Pharmacokinetics of Biologics
Alan C. Moss

2. Anti-tumor Necrosis Factor Agents in Ulcerative Colitis 
Kindra Clark-Snustad, Ives Hot, Scott Lee

3. Anti-tumor Necrosis Factor Agents in Crohn’s Disease
Byron P. Vaughn

4. Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease 
Sarah Flier

5. Use of Biologics in the Postoperative Management of Crohn’s Disease
Benjamin H. Click, Miguel Reguiero

6. Biologics in Pregnancy and Breastfeeding
Jill K. J. Gaidos, Sunanda V. Kane

7. Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease
Parambir S. Dulai, Corey A. Siegel

8. Therapeutic Drug Monitoring of Biologic Agents
Frank
I. Scott, Mark T. Osterman
9. Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks
Afrin Kamal, Bret Lashner

10. Cessation of Biologics – Can it be Done?
Hang Hock Shim, Cynthia H. Seow

11. Biologic Therapy in Pediatric Inflammatory Bowel Disease 
Sona Patel, Jennifer Strople

12. Infectious Complications of Biologics
Renée M. Marchioni Beery, Joshua R. Korzenik

13. Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy
Julia Hughes, Millie D. Long

14. Non-infectious and Non-malignant Complications of Biologics 
Raymond Cross

15. Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances
Asher Kornbluth

16.
Anti-Integrin Agents in IBD: Efficacy and Risk of Complications
Jimmy K. Limdi, Francis A. Farraye

17. Novel Agents in Inflammatory Bowel Disease
Fernando Velayos

18. Quality, Safety, and Practical Considerations of Using Biologic Therapies
Gil Melmed

Adam S. Cheifetz, MD

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Joseph D. Feuerstein, MD

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Provides a comprehensive and state-of-the-art overview of using biologics to treat IBD

Reviews best methods to effectively utilize biologics in the treatment of IBD

Written by experts in the field

Includes supplementary material: sn.pub/extras